セッション

糖尿病を対象とした有望な薬剤標的

新治療法への新しい取り組み

Incretinsの更なる調査

パネルディスカッション

トピック: 糖尿病の標的としてのIncretinsの将来

Participants:
Richard E. Pratley, M.D., Professor of Medicine and Director, Diabetes and Metabolism Translational Medicine Unit, University of Vermont College of Medicine
Rachele Berria, M.D., M.S.C.I., U.S. Medical Director, Diabetes Franchise, Roche Laboratories
Michael R. Hanley, Ph.D.,Chief Scientific Officer, Amylin Pharmaceuticals, Inc.

DISTINGUISHED FACULTY
Rachele Berria, M.D., Roche Laboratories
Elaine Chiquette, Amylin Pharmaceuticals Inc.
Max Dang, Ph.D., Metabasis Therapeutics, Inc.
Joseph Grimsby, Ph.D., F. Hoffmann-La Roche Inc.
Jesper Gromada, Ph.D., Novartis Institutes for BioMedical Research, Inc.
Michael R. Hanley, Ph.D., Amylin Pharmaceuticals, Inc.
Richard Ho, M.D., Ph.D., Rosa & Co. LLC.
Reid Huber, Ph.D., Metabolic Endocrine Drug Development, Incyte Corporation
Rob Jones, Ph.D., Arena Pharmaceuticals
Julia Lamenzo Ph.D., Harvard University
Daniel Lin, Ph.D., Amgen Inc.
Peter J. Oates, Ph.D., Pfi zer Global Research and Development
Norbert Perrimon, Ph.D., Harvard Medical School
Richard E. Pratley, M.D., University of Vermont College of Medicine
Jean Whaley, Ph.D., Bristol-Myers Squibb